Jiangsu Hengrui Medicine Co., Ltd.
Clinical trials sponsored by Jiangsu Hengrui Medicine Co., Ltd., explained in plain language.
A pharmaceutical company developing drugs in oncology, anesthesia, and more.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new daily pill slow advanced prostate cancer? Results expected Sep 2026 (estimated)
- Healthy volunteers to test new formulation of breast cancer drug HRS-6209 Results expected Sep 2026 (estimated)
- New pain jab could cut opioid use in kids after surgery Results expected Sep 2026 (estimated)
- New painkiller could ease recovery after lung surgery Results expected Nov 2026 (estimated)
- New hope for Hard-to-Treat lung cancer: targeted drug combo enters human trials Results expected Dec 2026 (estimated)
-
Can a new drug target HER2-Positive tumors that resist standard care?
Disease control Stopped earlyThis phase II trial is testing an experimental drug called SHR-4602 in people with advanced solid tumors that have HER2 expression or mutations. The drug is given by infusion every three weeks. The study aims to see if SHR-4602 can shrink tumors and how safe and tolerable it is. …
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Promising prostate cancer combo study halted early
Disease control Stopped earlyThis study tested whether adding the drug SHR3680 to standard hormone therapy could improve outcomes for men with high-risk prostate cancer before they had surgery to remove the prostate. The trial enrolled 391 participants and aimed to see if the combination could eliminate all …
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New inhaler for COPD shows promise in early trial
Disease control Stopped earlyThis study tested an experimental inhaled drug called HRG2005 in people with moderate to severe chronic obstructive pulmonary disease (COPD). The goal was to see if it improves lung function compared to a standard treatment. About 82 participants were enrolled, but the study was …
Phase 2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Lung cancer drug cocktail trial ends early – what we know
Disease control Stopped earlyThis phase 3 trial tested a combination of three drugs—camrelizumab (an immunotherapy), famitinib (a targeted therapy), and standard chemotherapy—in 48 people with advanced non-squamous non-small-cell lung cancer that did not have certain genetic changes. The study aimed to see i…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC